CoChat

BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth

Open access
Wang, Tao, Xiao, Min, Ge, Yingbin, Krepler, Clemens, Belser, Eric, Lopez-Coral, Alfonso, Xu, Xiaowei, Zhang, Gao, Azuma, Rikka, Liu, Qin, Liu, Rui, Li, Ling, Amaravadi, Ravi K., Xu, Wei, Karakousis, Giorgos, Gangadhar, Tara C., Schuchter, Lynn M., Lieu, Melissa, Khare, Sanika, Halloran, Molly B., Herlyn, Meenhard, Kaufman, Russel E. · 2015 · Clinical Cancer Research
Cited by 132

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

Purpose: To investigate the roles of melanoma-associated macrophages in melanoma resistance to BRAF inhibitors (BRAFi). Experimental Design: An in vitro macrophage and melanoma cell coculture system was used to investigate whether macrophages play a role in melanoma resistance to BRAFi. The effects of macrophages in tumor resistance were examined by proliferation assay, cell death assay, and Western blot analyses. Furthermore, two mouse preclinical models were used to validate whether targeting macrophages can increase the antitumor activity of BRAFi. Finally, the number of macrophages in melanoma tissues was examined by immunohistochemistry. Results: We demonstrate that in BRAF-mutant melanomas, BRAFi paradoxically activate the mitogen-activated protein kinase (MAPK) pathway in macrophages to produce VEGF, which reactivates the MAPK pathway and stimulates cell growth in melanoma cells. Blocking the MAPK pathway or VEGF signaling then reverses macrophage-mediated resistance. Targeting macrophages increases the antitumor activity of BRAFi in mouse and human tumor models. The presence of macrophages in melanomas predicts early relapse after therapy. Conclusions: Our findings demonstrate that macrophages play a critical role in melanoma resistance to BRAFi, suggesting that targeting macrophages will benefit patients with BRAF-mutant melanoma. Clin Cancer Res; 21(7); 1652–64. ©2015 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-14-1554

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 132

Metadata

Authors
Wang, T., Xiao, M., Ge, Y., Krepler, C., Belser, E., Lopez-Coral, A., Xu, X., Zhang, G., Azuma, R., Liu, Q., Liu, R., Li, L., Amaravadi, R. K., Xu, W., Karakousis, G., Gangadhar, T. C., Schuchter, L. M., Lieu, M., Khare, S., Halloran, M. B., Herlyn, M., & Kaufman, R. E.
Venue
Clinical Cancer Research
Published
2015-03-31
Volume
21
Issue
7
Pages
1652-1664
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W1971750711
Cited by
132
References
11
FWCI
5.15
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-14-1554
The paper
Wang, T., Xiao, M., Ge, Y., Krepler, C., Belser, E., Lopez-Coral, A., Xu, X., Zhang, G., Azuma, R., Liu, Q., Liu, R., Li, L., Amaravadi, R. K., Xu, W., Karakousis, G., Gangadhar, T. C., Schuchter, L. M., Lieu, M., Khare, S., . . . Kaufman, R. E. (2015). BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-14-1554

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.